vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是INTEGRA LIFESCIENCES HOLDINGS CORP的1.2倍（$540.7M vs $434.9M），INTEGRA LIFESCIENCES HOLDINGS CORP同比增速更快（-1.7% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-5.4M），过去两年INTEGRA LIFESCIENCES HOLDINGS CORP的营收复合增速更高（8.6% vs -2.3%）
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
IART vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.2倍
$434.9M
营收增速更快
IART
高出12.4%
-14.1%
自由现金流更多
ICUI
多$41.4M
$-5.4M
两年增速更快
IART
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $434.9M | $540.7M |
| 净利润 | — | $-15.7M |
| 毛利率 | 50.8% | 37.5% |
| 营业利润率 | 5.3% | 1.0% |
| 净利率 | — | -2.9% |
| 营收同比 | -1.7% | -14.1% |
| 净利润同比 | — | 34.0% |
| 每股收益（稀释后） | $-0.03 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IARTICUI
| Q4 25 | $434.9M | $540.7M | ||
| Q3 25 | $402.1M | $537.0M | ||
| Q2 25 | $415.6M | $548.9M | ||
| Q1 25 | $382.7M | $604.7M | ||
| Q4 24 | $442.6M | $629.8M | ||
| Q3 24 | $380.8M | $589.1M | ||
| Q2 24 | $418.2M | $596.5M | ||
| Q1 24 | $368.9M | $566.7M |
净利润IARTICUI
| Q4 25 | — | $-15.7M | ||
| Q3 25 | $-5.4M | $-3.4M | ||
| Q2 25 | $-484.1M | $35.3M | ||
| Q1 25 | $-25.3M | $-15.5M | ||
| Q4 24 | — | $-23.8M | ||
| Q3 24 | $-10.7M | $-33.0M | ||
| Q2 24 | $-12.4M | $-21.4M | ||
| Q1 24 | $-3.3M | $-39.5M |
毛利率IARTICUI
| Q4 25 | 50.8% | 37.5% | ||
| Q3 25 | 51.5% | 37.4% | ||
| Q2 25 | 50.4% | 37.9% | ||
| Q1 25 | 50.8% | 34.7% | ||
| Q4 24 | 56.3% | 36.1% | ||
| Q3 24 | 52.6% | 34.8% | ||
| Q2 24 | 54.0% | 34.8% | ||
| Q1 24 | 56.1% | 32.7% |
营业利润率IARTICUI
| Q4 25 | 5.3% | 1.0% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | -123.4% | 1.9% | ||
| Q1 25 | -4.0% | 2.1% | ||
| Q4 24 | 8.0% | 6.0% | ||
| Q3 24 | -2.1% | 1.4% | ||
| Q2 24 | -0.7% | 1.3% | ||
| Q1 24 | 1.1% | -1.9% |
净利率IARTICUI
| Q4 25 | — | -2.9% | ||
| Q3 25 | -1.3% | -0.6% | ||
| Q2 25 | -116.5% | 6.4% | ||
| Q1 25 | -6.6% | -2.6% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -2.8% | -5.6% | ||
| Q2 24 | -3.0% | -3.6% | ||
| Q1 24 | -0.9% | -7.0% |
每股收益（稀释后）IARTICUI
| Q4 25 | $-0.03 | $-0.63 | ||
| Q3 25 | $-0.07 | $-0.14 | ||
| Q2 25 | $-6.31 | $1.43 | ||
| Q1 25 | $-0.33 | $-0.63 | ||
| Q4 24 | $0.25 | $-0.97 | ||
| Q3 24 | $-0.14 | $-1.35 | ||
| Q2 24 | $-0.16 | $-0.88 | ||
| Q1 24 | $-0.04 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $263.7M | — |
| 总债务越低越好 | $726.6M | — |
| 股东权益账面价值 | $1.0B | $2.1B |
| 总资产 | $3.6B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资IARTICUI
| Q4 25 | $263.7M | — | ||
| Q3 25 | $267.9M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $273.3M | — | ||
| Q4 24 | $273.6M | $308.6M | ||
| Q3 24 | $277.6M | $312.5M | ||
| Q2 24 | $296.9M | $302.6M | ||
| Q1 24 | $663.1M | $251.4M |
总债务IARTICUI
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
股东权益IARTICUI
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $1.0B | $2.1B | ||
| Q2 25 | $1.0B | $2.1B | ||
| Q1 25 | $1.5B | $2.0B | ||
| Q4 24 | $1.5B | $2.0B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.6B | $2.1B |
总资产IARTICUI
| Q4 25 | $3.6B | $4.1B | ||
| Q3 25 | $3.6B | $4.1B | ||
| Q2 25 | $3.7B | $4.1B | ||
| Q1 25 | $4.1B | $4.2B | ||
| Q4 24 | $4.0B | $4.2B | ||
| Q3 24 | $4.1B | $4.3B | ||
| Q2 24 | $4.1B | $4.3B | ||
| Q1 24 | $4.1B | $4.3B |
负债/权益比IARTICUI
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-5.4M | $36.0M |
| 自由现金流率自由现金流/营收 | -1.2% | 6.6% |
| 资本支出强度资本支出/营收 | 4.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-31.1M | $91.8M |
8季度趋势，按日历期对齐
经营现金流IARTICUI
| Q4 25 | $11.8M | $60.6M | ||
| Q3 25 | $40.9M | $56.7M | ||
| Q2 25 | $8.9M | $11.2M | ||
| Q1 25 | $-11.3M | $51.3M | ||
| Q4 24 | $50.7M | $40.2M | ||
| Q3 24 | $22.5M | $36.1M | ||
| Q2 24 | $40.4M | $82.0M | ||
| Q1 24 | $15.8M | $45.8M |
自由现金流IARTICUI
| Q4 25 | $-5.4M | $36.0M | ||
| Q3 25 | $25.8M | $27.6M | ||
| Q2 25 | $-11.2M | $-8.5M | ||
| Q1 25 | $-40.2M | $36.7M | ||
| Q4 24 | $21.1M | $16.1M | ||
| Q3 24 | $-7.2M | $16.2M | ||
| Q2 24 | $10.7M | $62.5M | ||
| Q1 24 | $291.0K | $29.9M |
自由现金流率IARTICUI
| Q4 25 | -1.2% | 6.6% | ||
| Q3 25 | 6.4% | 5.1% | ||
| Q2 25 | -2.7% | -1.5% | ||
| Q1 25 | -10.5% | 6.1% | ||
| Q4 24 | 4.8% | 2.6% | ||
| Q3 24 | -1.9% | 2.7% | ||
| Q2 24 | 2.6% | 10.5% | ||
| Q1 24 | 0.1% | 5.3% |
资本支出强度IARTICUI
| Q4 25 | 4.0% | 4.6% | ||
| Q3 25 | 3.8% | 5.4% | ||
| Q2 25 | 4.8% | 3.6% | ||
| Q1 25 | 7.6% | 2.4% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.8% | 3.4% | ||
| Q2 24 | 7.1% | 3.3% | ||
| Q1 24 | 4.2% | 2.8% |
现金转化率IARTICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
